ABBVAbbVieRunning, no new patients
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
High Grade Ovarian Cancer · Primary Peritoneal Cancer · Fallopian Tube Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 125 (final count)
- Started
- Sep 28, 2022
- Main results expected
- Nov 2026
- Fully finished
- Nov 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Response Rate (ORR)
Measured over: Up to 3 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05456685 · record last updated 2025-10-28 · checked 2026-11-09 15:47 UTC